Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biotechnology company focused on targeted protein degradation (TPD). Through these filings, investors can review how Kymera reports its clinical progress, collaboration agreements, financing activities and corporate governance matters.
Kymera’s current reports on Form 8-K disclose material events such as clinical data presentations for KT-621, an investigational first-in-class oral STAT6 degrader in atopic dermatitis and asthma, and updates on KT-579, an oral IRF5 degrader for immune-mediated diseases. 8-K filings also describe key collaboration developments, including the IRAK4 degrader KT-485/SAR447971 with Sanofi for immuno-inflammatory diseases and an exclusive option and license agreement with Gilead Sciences covering an oral CDK2 molecular glue degrader program for potential use in breast cancer and other solid tumors.
Filings related to public offerings and capital structure outline Kymera’s underwritten offerings of common stock and pre-funded warrants, shelf registration statements on Form S-3 and associated underwriting agreements and registration rights agreements. These documents explain how the company raises capital to advance its pipeline of preclinical and clinical degrader programs and may detail potential milestone and royalty structures under collaboration arrangements.
Users can also consult SEC filings for information on Nasdaq listing details, including the KYMR ticker on The Nasdaq Global Market, as well as shareholder meeting results, board composition and executive transitions. Stock Titan’s platform pairs these filings with AI-powered summaries that highlight key terms, material developments and financial implications, helping readers navigate complex documents such as 8-Ks, registration statements and related exhibits more efficiently.
Kymera Therapeutics, Inc. director-associated venture funds reported open-market sales of a combined 81,866 shares of common stock at a weighted average price of about $90.13 per share. Atlas Venture Fund X, L.P. sold 71,814 shares and Atlas Venture Opportunity Fund I, L.P. sold 10,052 shares on March 2, 2026.
These trades were executed under a Rule 10b5-1 trading plan adopted on December 11, 2025. Bruce Booth is a member of the general partner entities of these funds and disclaims Section 16 beneficial ownership of the funds’ holdings except to the extent of his pecuniary interest.
Kymera Therapeutics submitted a Rule 144 notice for proposed sales of common stock, including 5,613 shares and 5,000 shares acquired upon RSU vesting.
The filing shows the 5,613 shares were acquired on 03/01/2026 and the 5,000 shares were acquired on 03/03/2026, both under the 2020 Equity Incentive Plan. It also reports prior sales of 49,307 shares on 12/08/2025 for aggregate proceeds of $3,284,832.34.
Kymera Therapeutics, Inc. filed a Form 144 reporting intent to sell shares acquired on vesting of Restricted Stock Units. The filing lists 2,039 shares tied to RSUs vested on 03/01/2026 and 4,167 shares tied to RSUs vested on 03/03/2026.
The transactions are noted as equity compensation sales through a broker on or about those dates; the filing provides the share counts and vesting basis but does not state sale prices or proceeds.
Kymera Therapeutics reported proposed sales of common stock under a Form 144. The notice lists two batches of shares tied to restricted stock units that vested under the 2020 Equity Incentive Plan: 7,576 shares on 03/01/2026 and 5,000 shares on 03/03/2026. The shares are described as acquired upon vesting and are listed with a broker on NASDAQ.
Kymera Therapeutics, Inc. established an at-the-market stock offering program allowing it to sell up to $500,000,000 of common shares through TD Securities (USA) LLC, which will act on a best efforts basis for sales on Nasdaq and other permitted methods.
The company will pay TD Cowen a commission of up to 3.0% of gross proceeds and may start, pause, or terminate sales at its discretion. Separately, Kymera filed a resale prospectus supplement registering the potential resale by certain existing investors of up to 18,819,826 outstanding common shares and 12,565,253 shares issuable upon exercise of pre-funded warrants at an exercise price of $0.0001 per warrant. Kymera will not receive proceeds from any resale of these shares, and will receive cash only if the warrants are exercised for cash.
Kymera Therapeutics is registering for resale up to 31,385,079 shares of its common stock. This amount consists of 18,819,826 shares plus up to 12,565,253 shares issuable upon exercise of pre-funded warrants, and the registration is to permit resale by the selling stockholders.
The registration is a resale registration under a registration rights agreement; Kymera states it will not receive proceeds from secondary sales, although cash exercises of the pre-funded warrants would yield proceeds equal to the $0.0001 exercise price per share. The prospectus cites February 26, 2026 and reports the registered shares represent approximately 38% of outstanding shares as of February 20, 2026.
Kymera Therapeutics filed a prospectus supplement to sell up to $500,000,000 of common stock in an at-the-market offering through TD Securities (USA) LLC (TD Cowen).
The prospectus states TD Cowen will act as sales agent and may sell shares in negotiated transactions, block trades or on Nasdaq, with compensation up to 3.0% of gross proceeds. The document uses an illustrative price of $91.01 per share (last reported sale price on February 24, 2026) and assumes 5,493,901 shares for illustrative proceeds of $500.0 million. Shares outstanding were 81,323,532 as of December 31, 2025. The company states proceeds, if any, would be used to fund research and clinical development, and for working capital and general corporate purposes.
Kymera Therapeutics files its annual report describing a clinical-stage pipeline built around targeted protein degradation, aiming to create oral small‑molecule medicines with biologics‑like efficacy. The company focuses mainly on immunology, targeting large populations with Type 2 and autoimmune diseases that remain poorly served by current therapies.
Lead STAT6 degrader KT-621 has completed Phase 1 studies and a Phase 1b atopic dermatitis trial, showing deep STAT6 degradation, broad Type 2 biomarker reductions and meaningful improvements in skin scores and itch, supporting ongoing Phase 2b trials in atopic dermatitis and asthma. IRF5 degrader KT-579 has entered Phase 1 after preclinical data showing potent, selective degradation and strong activity in lupus and arthritis models.
The report highlights collaborations: with Sanofi on IRAK4 degraders, where Kymera has received multiple milestones and Sanofi plans clinical testing of KT‑485/SAR447971 in 2026, and with Gilead on CDK2 molecular glue degraders in oncology, including a $40 million upfront payment and future milestone and royalty potential. Kymera details an extensive patent estate around its ligase ligands, degraders and targets, and notes reliance on third‑party manufacturers and contract research partners, along with substantial ongoing funding needs and typical biotech risks.